JP7295871B2 - 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用 - Google Patents

修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用 Download PDF

Info

Publication number
JP7295871B2
JP7295871B2 JP2020541689A JP2020541689A JP7295871B2 JP 7295871 B2 JP7295871 B2 JP 7295871B2 JP 2020541689 A JP2020541689 A JP 2020541689A JP 2020541689 A JP2020541689 A JP 2020541689A JP 7295871 B2 JP7295871 B2 JP 7295871B2
Authority
JP
Japan
Prior art keywords
ttds
group
palm
amino acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020541689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512099A (ja
JP2021512099A5 (cg-RX-API-DMAC7.html
Inventor
オリヴィエ・デュクロ
ステファンヌ・イリアーノ
セルジオ・マラルト
クレール・ミノレッティ-オーシェピエ
エリザベッタ・ビアンキ
ラファイーレ・インジェニート
パオラ・マゴッティ
アレッシア・サントプレテ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2021512099A publication Critical patent/JP2021512099A/ja
Publication of JP2021512099A5 publication Critical patent/JP2021512099A5/ja
Application granted granted Critical
Publication of JP7295871B2 publication Critical patent/JP7295871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020541689A 2018-01-31 2019-01-30 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用 Active JP7295871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094.7 2018-01-31
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (3)

Publication Number Publication Date
JP2021512099A JP2021512099A (ja) 2021-05-13
JP2021512099A5 JP2021512099A5 (cg-RX-API-DMAC7.html) 2022-02-02
JP7295871B2 true JP7295871B2 (ja) 2023-06-21

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541689A Active JP7295871B2 (ja) 2018-01-31 2019-01-30 修飾された脂質化リラキシンb鎖ペプチドおよびその治療的使用

Country Status (29)

Country Link
US (3) US10961295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746467B1 (cg-RX-API-DMAC7.html)
JP (1) JP7295871B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755938B1 (cg-RX-API-DMAC7.html)
CN (1) CN111770934B (cg-RX-API-DMAC7.html)
AR (1) AR114325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019214358B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089657A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008308A2 (cg-RX-API-DMAC7.html)
DK (1) DK3746467T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058633T3 (cg-RX-API-DMAC7.html)
FI (1) FI3746467T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260016T1 (cg-RX-API-DMAC7.html)
IL (2) IL276170B2 (cg-RX-API-DMAC7.html)
LT (1) LT3746467T (cg-RX-API-DMAC7.html)
MA (1) MA52994A (cg-RX-API-DMAC7.html)
MX (1) MX2020008096A (cg-RX-API-DMAC7.html)
MY (1) MY199821A (cg-RX-API-DMAC7.html)
NZ (1) NZ766762A (cg-RX-API-DMAC7.html)
PH (1) PH12020551118A1 (cg-RX-API-DMAC7.html)
PL (1) PL3746467T3 (cg-RX-API-DMAC7.html)
PT (1) PT3746467T (cg-RX-API-DMAC7.html)
RS (1) RS67606B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006903WA (cg-RX-API-DMAC7.html)
SI (1) SI3746467T1 (cg-RX-API-DMAC7.html)
TW (1) TWI763972B (cg-RX-API-DMAC7.html)
UY (1) UY38069A (cg-RX-API-DMAC7.html)
WO (1) WO2019149782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157829A1 (en) 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
JP2016531156A (ja) 2013-09-13 2016-10-06 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、及びその組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288011A1 (en) * 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531156A (ja) 2013-09-13 2016-10-06 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、及びその組成物
WO2015157829A1 (en) 2014-04-17 2015-10-22 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HOSSAIN M A; ET AL,THE MINIMAL ACTIVE STRUCTURE OF HUMAN RELAXIN-2,JOURNAL OF BIOLOGICAL CHEMISTRY,2011年10月28日,VOL:286, NR:43,,PAGE(S):37555 - 37565,https://doi.org/10.1074/jbc.M111.282194
MOHAMMED AKHTER HOSSAIN; ET AL,A SINGLE-CHAIN DERIVATIVE OF THE RELAXIN HORMONE IS A FUNCTIONALLY SELECTIVE AGONIST OF THE G PROTEIN-COUPLED RECEPTOR, RXFP1,CHEMICAL SCIENCE,2016年,VOL:7, NR:6,,PAGE(S):3805 - 3819,http://dx.doi.org/10.1039/C5SC04754D
MOHAMMED AKHTER HOSSAIN; ET AL,SYNTHETIC RELAXINS,CURRENT OPINION IN CHEMICAL BIOLOGY,2014年10月,PAGE(S):47-55,http://dx.doi.org/10.1016/j.cbpa.2014.09.014

Also Published As

Publication number Publication date
PL3746467T3 (pl) 2026-04-13
PT3746467T (pt) 2026-01-13
US20240218042A1 (en) 2024-07-04
CN111770934B (zh) 2024-10-18
US10961295B2 (en) 2021-03-30
AR114325A1 (es) 2020-08-19
AU2019214358A1 (en) 2020-08-20
CA3089657A1 (en) 2019-08-08
JP2021512099A (ja) 2021-05-13
US20190233494A1 (en) 2019-08-01
SI3746467T1 (sl) 2026-02-27
DK3746467T3 (da) 2026-01-12
RU2020126210A (ru) 2022-02-28
CN111770934A (zh) 2020-10-13
IL276170B2 (en) 2025-03-01
US11725036B2 (en) 2023-08-15
SG11202006903WA (en) 2020-08-28
IL276170B1 (en) 2024-11-01
UY38069A (es) 2019-08-30
TWI763972B (zh) 2022-05-11
KR102755938B1 (ko) 2025-01-20
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
MA52994A (fr) 2021-05-05
US20210292387A1 (en) 2021-09-23
MX2020008096A (es) 2020-09-24
TW201940505A (zh) 2019-10-16
EP3746467B1 (en) 2025-10-08
HRP20260016T1 (hr) 2026-02-27
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
CO2020008308A2 (es) 2020-10-30
MY199821A (en) 2023-11-23
KR20200116085A (ko) 2020-10-08
AU2019214358B2 (en) 2023-05-25
LT3746467T (lt) 2026-01-26
IL316406A (en) 2024-12-01
IL276170A (en) 2020-09-30
ES3058633T3 (en) 2026-03-12
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
PH12020551118A1 (en) 2021-07-05

Similar Documents

Publication Publication Date Title
KR102755938B1 (ko) 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
US10988524B2 (en) Modified relaxin B chain peptides and their therapeutic use
US20240400638A1 (en) Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
WO2023161229A1 (en) Crf2 receptor agonists and their use in therapy
RU2804702C2 (ru) Модифицированные липидированные пептиды b-цепи релаксина и их терапевтическое применение
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230609

R150 Certificate of patent or registration of utility model

Ref document number: 7295871

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250